This web page was created programmatically, to learn the article in its unique location you possibly can go to the hyperlink bellow: https://www.medpagetoday.com/pediatrics/obesity/121871and if you wish to take away this text from our web site please contact us [ad_1] An estimated 17 million U.S. adolescents and younger adults have been discovered to be eligible for GLP-1 receptor agonist remedy, although many lack insurance coverage or a routine place for healthcare.In a scientific overview and meta-analysis, remedy with the GLP-1 receptor agonist semaglutide plus counseling was related to the most important BMI discount and BMI z rating discount.Lifestyle remedies alone had been additionally related to substantial decreases in BMI and BMI z rating versus no structured weight administration plan. Pharmacotherapies paired with way of life remedies had been linked with the best short-term weight discount in children and youths with weight problems, a scientific overview and community meta-analysis confirmed. Treatment with the GLP-1 receptor agonist semaglutide (Wegovy) plus counseling was related to the most important physique mass index (BMI) discount (imply distinction -8.31, 95% CI -12.33 to -4.28) and BMI z rating discount (imply distinction -1.80, 95% CI -2.39 to -1.21), reported Bjorn Tam, PhD, of Hong Kong Baptist University, and colleagues in JAMA Pediatrics. While semaglutide with counseling "emerged as the most potent intervention ... this estimate comes from a single trial with relatively few participants," the authors famous. As a outcome, they graded the knowledge of proof for this comparability as reasonable. Overall, Tam and colleagues examined a wide range of interventions and comparators throughout 42 randomized trials:Lifestyle remedies -- counseling, well being conduct and way of life remedy (HBLT), and intensive HBLT (a minimum of 26 hours)Pharmacological interventions -- GLP-1 receptor agonists (liraglutide [Saxenda], semaglutide, dulaglutide [Trulicity], and exenatide [Byetta]) and different drugs (orlistat [Alli], phentermine-topiramate [Qsymia], and metformin)Combination therapies -- HBLT, intensive HBLT, or counseling with pharmacotherapy More than 350 million folks ages 5 to 14 years and 390 million folks ages 15 to 24 years are projected to have chubby or weight problems by 2050. In the U.S. alone, an estimated 17 million adolescents and younger adults have been discovered to be eligible for GLP-1 receptor agonist remedy, although many lack insurance coverage or a routine place for healthcare. The rising prevalence of weight problems is linked to critical comorbidities, equivalent to sort 2 diabetes, heart problems, psychosocial misery, and others, Tam and colleagues famous. "The profound health consequences and alarming trajectory of this epidemic underscore the urgent need for effective prevention and intervention strategies," they wrote. However, "direct head-to-head comparisons of structured HBLT (by intensity), various pharmacotherapies (both FDA approved and off-label), and combined therapeutic strategies are scarce." In this research, pharmacotherapy plus way of life remedy "demonstrated the greatest efficacy across all adiposity-related outcomes," they added. Moreover, all drugs had been simpler with way of life remedy in contrast with the identical drugs alone. "Our analysis ... suggests that lifestyle treatment was essential and should form the backbone of any pediatric obesity treatment plan," they famous. HBLT as monotherapy was additionally related to substantial decreases in BMI (imply distinction -3.85, 95% CI -4.91 to -2.80) and BMI z rating (imply distinction -0.89, 95% CI -1.17 to -0.61) versus no structured weight administration plan. "Notably, these decreases were larger than those achieved by any of the individual pharmacotherapies included in our network when used as monotherapy (liraglutide and metformin)," Tam and colleagues identified. For this systematic overview and community meta-analysis, Tam and colleagues searched Embase, Central, PsycInfo, and PubMed from inception to June 17, 2025. They included 42 randomized trials, most of which (57%) had been carried out in North America. The trials comprised 3,835 individuals, with a imply age of 14.5 years. Nearly 60% of individuals had been feminine. Looking at secondary outcomes, semaglutide plus counseling was related to the most important lower in waist circumference (imply distinction -16.70 cm, 95% CI -31.57 to -1.83), whereas metformin with intensive HBLT confirmed the most important discount in fats mass (standardized imply distinction [SMD] -2.53, 95% CI -3.97 to -1.09), although Tam and colleagues famous that intensive HBLT monotherapy was additionally tied to a sturdy discount (SMD -2.19, 95% CI -3.04 to -1.33). For lean mass, exenatide with HBLT was linked to a major loss (imply distinction -4.30 kg, 95% CI -8.33 to -0.27), as was metformin alone (imply distinction -2.00 kg, 95% CI -3.99 to -0.01). Limitations of the research included that findings for newer medicine like GLP-1 agonists and phentermine-topiramate relied on just a few trials with small pattern sizes, and that age was not recognized as a major remedy modifier, Tam and colleagues famous. Inherent heterogeneity remained relating to elements, period, and depth of way of life applications, in addition to medicine dosages, "potentially influencing outcome magnitudes," they added, and a lot of the trials had been brief to medium period (6 months to 1 yr). Please allow JavaScript to view the comments powered by Disqus. [ad_2] This web page was created programmatically, to learn the article in its unique location you possibly can go to the hyperlink bellow: https://www.medpagetoday.com/pediatrics/obesity/121871and if you wish to take away this text from our web site please contact us